Joel Greenblatt's AKBA Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 15,970 shares of Akebia Therapeutics, Inc. (AKBA) worth $25,712, representing 0.00% of the portfolio. First purchased in 2021-Q2, this short-term holding has been held for 5 quarters.
Based on 13F filings, Joel Greenblatt has maintained this position in AKBA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 15,569 shares. Largest reduction occurred in Q3 2021, reducing 19,195 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Akebia Therapeutics (AKBA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Akebia Therapeutics (AKBA) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1,471 | Add 10.15% | 15,970 | $1.61 |
| Q3 2025 | -1,070 | Reduce 6.87% | 14,499 | $2.73 |
| Q2 2025 | +15,569 | New Buy | 15,569 | $3.64 |
| Q3 2021 | -19,195 | Sold Out | 0 | $0.00 |
| Q2 2021 | +19,195 | New Buy | 19,195 | $3.80 |
Joel Greenblatt's Akebia Therapeutics Investment FAQs
Joel Greenblatt first purchased Akebia Therapeutics, Inc. (AKBA) in Q2 2021, acquiring 19,195 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Akebia Therapeutics, Inc. (AKBA) for 5 quarters since Q2 2021.
Joel Greenblatt's largest addition to Akebia Therapeutics, Inc. (AKBA) was in Q2 2021, adding 19,195 shares worth $73,000.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 15,970 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $25,712.
As of the Q4 2025 filing, Akebia Therapeutics, Inc. (AKBA) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Akebia Therapeutics, Inc. (AKBA) was 19,195 shares, as reported at the end of Q2 2021.